Browsing Category
Bio space
2045 posts
Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing
Oncology Pharma Inc. (OTC PINK:ONPH) Pursuant to previously announced press release, Oncology Pharma, Inc. has retained the services…
Immunovia Appoints New Chief Financial Officer
Immunovia AB (publ) (“Immunovia”), a diagnostic company that develops and sells highly accurate blood tests for the early…
IMFINZI Plus Tremelimumab Significantly Improved Overall Survival in HIMALAYA Phase III Trial in 1st-Line Unresectable Liver Cancer
Positive high-level results from the HIMALAYA Phase III trial showed a single, high priming dose of tremelimumab added…
Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn® Disinfectant & Sanitizer Has Been Approved by the Australia TGA with a 15 Second SARS-CoV-2 (COVID-19) Kill Time
Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn ® Disinfectant & Sanitizer Has Been Approved by the Australia…
Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Medicines…
Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
Bristol Myers Squibb (NYSE:BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European…
Dr. Reddy’s Laboratories Announces the Launch of Carmustine for Injection, USP in the U.S. Market
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred…
Akeso is Rapidly Advancing The Phase II Clinical Trial of IL-4R Monoclonal Antibody (AK120) for the Treatment of Atopic Dermatitis and Asthma
Akeso, Inc. announces that the Company’s self-developed innovative drug candidate, IL-4R monoclonal antibody, was approved by the Center…
Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Dosing of Last Patient in Phase III BALANCE Clinical Trial PRX-102 for the Treatment of Fabry Disease
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), and Chiesi Global Rare Diseases, today announced the final dosing…
Aspaveli® (pegcetacoplan) receives positive CHMP opinion for treatment of PNH
Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announce today that the Committee…
